Literature DB >> 3631999

Treatment of toxic epidermal necrolysis. Créteil's experience.

J Revuz, J C Roujeau, J C Guillaume, D Penso, R Touraine.   

Abstract

Mesh:

Substances:

Year:  1987        PMID: 3631999

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  7 in total

Review 1.  Clinical features and management of severe dermatological reactions to drugs.

Authors:  M C Raviglione; A Pablos-Mendez; R Battan
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

2.  A case of toxic epidermal necrolysis (ten) with severe chronic ocular complications in a healthy 46-year-old woman.

Authors:  A Voltan; B Azzena
Journal:  Ann Burns Fire Disasters       Date:  2010-06-30

3.  Toxic Epidermal Necrolysis in Recessive Dystrophic Epidermolysis Bullosa following Bone Marrow Transplantation.

Authors:  Christina L Boull; Sara A Hylwa; Dusan Sajic; John E Wagner; Jakub Tolar; Kristen P Hook
Journal:  J Pediatr       Date:  2016-03-11       Impact factor: 4.406

Review 4.  Allergic emergencies encountered by the dermatologist. Severe cutaneous adverse drug reactions.

Authors:  P Wolkenstein; J Revuz
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 10.817

5.  Stevens Johnson syndrome after carbamazepine and SJS/TEN overlap syndrome after amoxicillin: case reports and a review.

Authors:  Krystyna Romańska-Gocka; Jacek Gocki; Waldemar Placek; Barbara Zegarska; Paweł Krause
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

6.  Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study.

Authors:  F Lebargy; P Wolkenstein; M Gisselbrecht; F Lange; J Fleury-Feith; C Delclaux; E Roupie; J Revuz; J C Roujeau
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

7.  Drug induced toxic epidermal necrolysis: two case reports.

Authors:  Syed Nurul Rasool Qadir; Naeem Raza; Fozi Qadir
Journal:  Cases J       Date:  2009-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.